The Valley Desk

NCT05687266 · Interventional trial

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Overall registry status Active not recruiting

Phase 3

Conditions NSCLC

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov